Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-arterial Lutetium-177-dotatate for neuroendocrine tumor liver metastases
2017-000369-54Phase 2Active
- Sponsor
- University Medical Center Utrecht
- Start
- Jun 2018
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lutetium Lu 177 dotatate in apudoma (NET), sponsored by University Medical Center Utrecht. Primary endpoint: Tumor-to-non-tumor activity concentration ratio on SPECT/CT (primary). Started Jun 2018; status: active.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on 2017-000369-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000369-54.